載入中
JPXHealthcareDrug Manufacturers - Specialty & Generic
最新資料
¥27.00
+¥1.00 · +3.85%
Established in 2006 and headquartered in Tokyo, Japan, Solasia Pharma K.K. is dedicated to the development and commercialization of oncology treatments throughout Japan and other parts of Asia. The company's marketed products include SP-03 (episil oral liquid), designed for the protection and relief of oral pain and inflammation (mucositis/stomatitis) resulting from cancer chemotherapy and radiation. Additionally, they offer SP-01 (Sancuso), a transdermal patch that delivers granisetron, an anti-emetic, into the bloodstream to manage chemotherapy-induced nausea and vomiting. Solasia Pharma's development pipeline features SP-02 (Darinaparsin), a mitochondrial-targeted agent that has successfully completed Phase III clinical trials for a range of hematologic and solid cancers. Also in Phase III clinical study is SP-05 (Arfolitixorin), which aims to bolster the anti-tumor effectiveness of fluorouracil in various cancers, including pancreatic, breast, stomach, and head and neck cancers. In its pre-clinical stage, SP-04 is being developed to address chemotherapy-induced peripheral neuropathy.
最新資料
¥27.00
+¥1.00 · +3.85%
盤中時間採用JST。市場資料可能有所延遲。
Established in 2006 and headquartered in Tokyo, Japan, Solasia Pharma K.K. is dedicated to the development and commercialization of oncology treatments throughout Japan and other parts of Asia. The company's marketed products include SP-03 (episil oral liquid), designed for the protection and relief of oral pain and inflammation (mucositis/stomatitis) resulting from cancer chemotherapy and radiation. Additionally, they offer SP-01 (Sancuso), a transdermal patch that delivers granisetron, an anti-emetic, into the bloodstream to manage chemotherapy-induced nausea and vomiting. Solasia Pharma's development pipeline features SP-02 (Darinaparsin), a mitochondrial-targeted agent that has successfully completed Phase III clinical trials for a range of hematologic and solid cancers. Also in Phase III clinical study is SP-05 (Arfolitixorin), which aims to bolster the anti-tumor effectiveness of fluorouracil in various cancers, including pancreatic, breast, stomach, and head and neck cancers. In its pre-clinical stage, SP-04 is being developed to address chemotherapy-induced peripheral neuropathy.
日內區間
目前¥27.00
52週區間
目前¥27.00
盤中時間採用JST。市場資料可能有所延遲。
Established in 2006 and headquartered in Tokyo, Japan, Solasia Pharma K.K. is dedicated to the development and commercialization of oncology treatments throughout Japan and other parts of Asia. The company's marketed products include SP-03 (episil oral liquid), designed for the protection and relief of oral pain and inflammation (mucositis/stomatitis) resulting from cancer chemotherapy and radiation. Additionally, they offer SP-01 (Sancuso), a transdermal patch that delivers granisetron, an anti-emetic, into the bloodstream to manage chemotherapy-induced nausea and vomiting. Solasia Pharma's development pipeline features SP-02 (Darinaparsin), a mitochondrial-targeted agent that has successfully completed Phase III clinical trials for a range of hematologic and solid cancers. Also in Phase III clinical study is SP-05 (Arfolitixorin), which aims to bolster the anti-tumor effectiveness of fluorouracil in various cancers, including pancreatic, breast, stomach, and head and neck cancers. In its pre-clinical stage, SP-04 is being developed to address chemotherapy-induced peripheral neuropathy.
日內區間
目前¥27.00
52週區間
目前¥27.00
獲利能力占已公布營收的百分比。
營收
營業利益
淨利
| 項目（JPY） | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 營收 | 4.29億 JPY | 3.16億 JPY | 6.17億 JPY | 10.92億 JPY | 5.59億 JPY |
| 銷貨成本 | 2.58億 JPY | 3.26億 JPY | 7.8億 JPY | 9.64億 JPY | 6.8億 JPY |
| 毛利 | 1.71億 JPY | −1000萬 JPY | −1.63億 JPY | 1.28億 JPY | −1.21億 JPY |
| 研究與開發 | 4.3億 JPY | 4.14億 JPY | 4.03億 JPY | 8.83億 JPY | 8.45億 JPY |
| 銷售、一般及管理費用 | 6.37億 JPY | 5.67億 JPY | 5.73億 JPY | 9.74億 JPY | 14.53億 JPY |
| 營業費用 | 10.3億 JPY | 9.81億 JPY | 9.76億 JPY | 18.57億 JPY | 22.98億 JPY |
| 利息收入 | 100萬 JPY | — | 1000萬 JPY | — | — |
| 利息支出 | 1400萬 JPY | 500萬 JPY | — | 1800萬 JPY | 2300萬 JPY |
| 折舊和攤銷 | 3700萬 JPY | 1.95億 JPY | 5億 JPY | 5.34億 JPY | 4.95億 JPY |
| 營業利益 | −8.59億 JPY | −9.91億 JPY | −11.39億 JPY | −17.29億 JPY | −24.19億 JPY |
| 淨利 | −8.76億 JPY | −19.41億 JPY | −11.12億 JPY | −25.48億 JPY | −24.78億 JPY |
公司資料更新於 2026年10月18日。
近期已公布業績
近期已公布業績
報告持有此股票曝險的交易所交易基金。
AI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
